



- (51) International Patent Classification:
C07D 215/00 (2006.01)
- (21) International Application Number:
PCT/US2009/057291
- (22) International Filing Date:
17 September 2009 (17.09.2009)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
61/097,693 17 September 2008 (17.09.2008) US
- (71) Applicant (for all designated States except US): **UNIVERSITY OF CENTRAL FLORIDA RESEARCH FOUNDATION, INC.** [US/US]; 12201 Research Pkwy., Suite 501, Orlando, FL 32826-3246 (US).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): **TURKSON, James** [CA/US]; 9988 Savannah Bluff Lane, Orlando, FL 32829
- (US). **HAMILTON, Andrew, D.** [US/US]; 1 White Pine Lane, Guilford, CT 06437 (US).
- (74) Agent: **ESTEVEZ, Enrique, G.**; Allen, Dyer, Doppelt, Milbrath & Gilchrist, P.A., 255 South Orange Avenue, Ste. 1401, Orlando, FL 32801 (US).
- (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
- (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ,

[Continued on next page]

(54) Title: INHIBITORS OF STAT3






FIG. 1

(57) Abstract: Disclosed herein are compounds derived from a chemical structure according to the formula (I) wherein X comprises oxygen or sulfur, R¹ comprises a phenyl or naphthyl group, R² comprises an amide group and R³ comprises a phosphate group. The disclosed compounds demonstrate inhibitory activity against STAT3, a protein found in certain tumor tissues and which promotes cellular overproliferation and resistance to apoptosis. The invention includes compositions containing the disclosed compounds, as well as methods of treatment therewith.



TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, **Published:**

ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,

MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, SM,

TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,

ML, MR, NE, SN, TD, TG).

— *with international search report (Art. 21(3))*

INHIBITORS OF STAT3

RELATED APPLICATION

This application claims priority from U.S. provisional application Serial
5 No. 60/097,693, which was filed on 17 September 2008, and which is
incorporated herein by reference in its entirety.

STATEMENT OF GOVERNMENT RIGHTS

The invention claimed herein was made with at least partial support
10 from the U.S. Government. Accordingly, the government may have certain
rights in the invention, as specified by law.

FIELD OF THE INVENTION

The present invention relates to the field of cellular dysfunction
15 diseases such as cancer and, more particularly, to diseases characterized by
overexpression of STAT3 protein.

BACKGROUND OF THE INVENTION

STAT3 is the acronym for signal transducer and activator of
20 transcription 3. As the name implies, STAT3 is a transcription factor and, in
humans, it is encoded by the gene appropriately known as the STAT3 gene.

STAT3 is a protein which belongs in a family of related STAT proteins.
STAT proteins are phosphorylated in response to various growth factors and
cytokines which are associated with cell receptors. The phosphorylated STAT
25 proteins then form either homo or heterodimers which move into the cell
nucleus to function as transcription activators. Growth factors and cytokines
which are known to activate STAT proteins include IL5, IL6, LIF, IFNs, EGF
and BMP2.

STAT3 is known to be responsible for mediating expression of many
30 genes when the cell is exposed to stimuli. Accordingly, STAT3 has a central
role in important cellular processes involving cell growth and death, apoptosis.

Presence of constitutive STAT3 is found in a number of human cancers and has also been found to be an indicator of poor outcome. Constitutive STAT3 promotes cancerous cell growth by being anti-apoptotic and also stimulating uncontrolled cell proliferation.

5 Suppression of constitutive STAT3 protein activation in human malignancies represents an important target for molecular therapeutic intervention. STAT proteins mediate the relay of extracellular signals from various cell surface protein receptors to the nucleus, where they help to initiate and regulate specific anti-apoptotic and cell survival gene expression.
10 In part cular , the STAT3 protein isoform is known to directly up-regulate Bel-XL, c-Myc, Mel-I, VEGF and cyclin D1/ D2, contributing directly to compromised cellular regulation by stimulating cell proliferation and preventing apoptosis in numerous human cancers.

 STAT3 activation occurs via phosphorylation of tyrosine 705, which
15 promotes STAT dimerformation through reciprocal STAT phosphotyrosine-SH2 domain interactions." STAT dimers then translocate to the nucleus, where they regulate unique gene expression programs through interaction with specific DNA response elements. STAT3 targeted gene expression confers resistance to apoptosis in many tumor cells. and promotes cell
20 survival, contributing to the resistance of these cancers to currently available chemotherapeutics. Successful STAT3 inhibitors may thus be used to sensitize human cancers with constitutively active STAT3 to existing chemotherapeutic agents, potentially reducing the side effects associated with conventional, aggressive chemotherapy.

25 Despite the difficulties in identifying protein surface-recognition agents, the promise of STAT3 modulators warrants investigation. Successful peptidic and nonpeptidomimetic small molecules that are capable of targeting malignant cell lines with constitutively activated Stat3 protein are limited to a few examples that include Stattic, STA-21, and S3I-201, which were all
30 identified through high-throughput virtual or biochemical screening approaches. Our first-generation designs were simple peptidomimetics

derived from the natural sequence, of which ISS610 was the most potent (see FIG. 1). More recently we have discovered S3I-M2001 (compound 15, Table 1) an oxazole-based small-molecule inhibitor that shows promising inhibition of Stat3 function, and we herein report a family of rationally designed small-molecule, nonpeptidic Stat3 inhibitors.

These agents inhibit Stat3 protein dimerization and induce apoptosis in Stat3-transformed cells and Stat3-dependent breast oncogenic cell lines. The crystal structure of the Stat3-SH2 domain reveals a shallow triangular pocket that is composed of two hydrophobic sites and a hydrophilic phosphate-recognition pocket. Docking studies on our initial lead, peptidomimetic, ISS610, showed that only the hydrophobic pockets in the binding domain were effectively occupied (See FIG. 1 A). To address this problem we theorized that trisubstituted heterocyclic scaffolds, such as oxazoles and thiazoles, might effectively access all three sites (FIG. 1B).

SUMMARY OF THE INVENTION

With the foregoing in mind, the present invention discloses various small molecule compounds which are inhibitors of STAT3. Additionally, the invention includes compositions containing the disclosed STAT3 inhibitory compounds, as well as methods of treatment employing these compounds and compositions.

The present investigation sought to rationally develop small molecule probes derived from the native STAT3 binding sequence. Herein reported is the first rational design and synthesis of small molecule STAT3 inhibitors which selectively inhibit STAT3 protein dimerization and induce apoptosis in STAT3 transformed cells and STAT3-dependent breast and pancreatic oncogenic cell lines.

As noted above, the crystal structure of the STAT3-SH2 domain includes a shallow triangular pocket containing two hydrophobic sites and a hydrophilic phosphate-recognition pocket. Docking studies of the initial lead compound, peptidomimetic ISS610, indicated that only the hydrophobic pockets in the

binding domain were effectively occupied (See FIG. 1A). Therefore, it was theorized that perhaps trisubstituted heterocyclic scaffolds, such as oxazoles and thiazoles, might effectively access all three sites (FIG. 1B). Flexible ligand-docking studies (GOLD) directed the design and assembly of oxazole and thiazole scaffolds. The compounds of the present invention were prepared as outlined in the scheme shown in FIG. 2 and below; the thiazole derivatives were synthesized via traditional hantzsch synthetic protocols.

General Procedure A (Alkylation of N-(Diphenylmethylene)glycine ethyl ester): To a flame dried three necked flask under nitrogen and fitted with an over head mechanical stirrer was added N-(Diphenylmethylene)glycine ethyl ester (1 eq) and THF (2 mL/mmol). The resulting solution was cooled to -78°C, and LiHMDS (1.0 M, 1.1 eq) was added. A thick yellow precipitate forms slowly over 4 hours, at which time a solution of the required acid chloride (1.0 eq) in THF (1 mL/mmol) is added dropwise over 1 hour. After complete addition of the acid chloride, the resulting solution was allowed to warm slowly to room temperature over night, and then the reaction was quenched with 2M HCl (1 mL/mmol). The resulting solution was washed twice with EtOAc (1 mL/mmol), and the aqueous layer evaporated to dryness. The resulting solid was dissolved in methanol (0.5 mL/mmol), and an equal amount EtOAc added to induce complete precipitation of inorganic salts, which were then removed by filtration. The resulting solution was reduced to dryness, and the product used without further purification.

General Procedure B (Amide formation from Acids): The required acid (1.0 eq) was added in one portion to a solution of HBTU (1.1 eq) and DIPEA (3.0 eq) in DMF (1 mL/mmol), and the resulting solution stirred at room temperature for 10 minutes. The required amine was then dissolved in a solution of DIPEA (2.0 eq) in DMF (1 mL/mmol) and added to the activated acid in one portion. The resulting solution was stirred for 4 hours, then diluted with EtOAc (10 mL/mmol) and washed successively with equal volumes of: brine, 2M HCl, saturated bicarbonate and brine. The organic layer was dried

over magnesium sulfate, and the solvent was removed under reduced pressure to afford the desired amide.

General Procedure C (Oxazole formation): Iodine (1.1 eq) was added to a solution of triphenylphosphine (1.1 eq) dissolved in DCM (20 mL/mmol) in a flame dried flask under nitrogen, and the resulting yellow solution stirred for 5 minutes. TEA (2.2 eq) was then added and the solution stirred under nitrogen for a further 5 minutes. The required amide (1.0 eq) was dissolved in DCM (10 mL/mmol) and added dropwise over 10 minutes to the solution of triphenylphosphine diiodide. After stirring for 4 hours excess triphenylphosphine diiodide was quenched by addition of MeOH (5.0 eq), and the resulting solution absorbed directly onto silica gel, and purified by FCC.

General Procedure D (Base Ester Hydrolysis): An aqueous solution of sodium hydroxide (2M, 3 eq) was added to a solution of the required ester (1 eq) dissolved in 1:1 THF/Water (40 mL/mmol). The resulting solution was stirred at room temperature over night, and the pH raised to ~7 by addition of 2M HCl. The reaction was extracted into EtOAc (100 mL/mmol), and washed with brine (20 mL/mmol). The organic phase was dried over magnesium sulfate, and solvent removed under reduced pressure to afford the desired carboxylic acid.

General Procedure E (tert-butylation of carboxylic acid). The suitable carboxylic acid (1 equiv) was dissolved in CH₂Cl₂ (10 mL/mmol), to which tert-Butyl 3,3,3-trichloroacetamide (2 equiv) was added in a solution of cyclohexane (2 mL/mmol) followed by the addition of BF₃·etherate (20 µL/mmol). The reaction solution was then stirred at room temperature under an N₂ atmosphere for 2 hrs. The reaction was monitored by TLC, until all the starting material had been consumed.

General Procedure F (Hydrogenolysis of benzyl ether): The required benzyl protected phenol (1 equiv) was dissolved in a stirred solution of MeOH:EtOAc (1:1). The solution was then degassed thoroughly before the addition of Pd/C 10% (10 mg/mmol). H₂ gas was then bubbled through the solution for 5 mins before the solution was put under an atmosphere of H₂

gas and stirred continuously for 3 hrs. The hydrogen gas was excluded from the reaction vessel and the reaction mixture filtered to remove the Pd/C through glass fibre paper. The solution was then concentrated to give pure product.

5 General Procedure G (Phosphorylation with Phosphoramidate): The required phenol (1 equiv) was dissolved in DMF (1 mL/mmol), 3% w/w tetratrazole in acetonitrile (4 eq), and di-tert-butyl diisopropylphosphoramidate (1.5 eq) was added in one portion. The resulting solution was stirred at room temperature over night, then cooled in an ice bath and then m-CPBA (1.1 eq)
10 was added in small portions. The resulting solution was extracted into EtOAc (20 mL/mmol), and washed successively with 1M HCl, saturated sodium bicarbonate, and brine. The organic phase was dried over magnesium sulfate, and the solvent was removed under reduced pressure.

 General Procedure H (tButyl ester TFA mediated deprotection): To a
15 stirred solution of tert-butyl ester (1 eq) in CH₂Cl₂ (1 mL/mmol) under N₂ was added dropwise trifluoroacetic acid (100 equiv) and allowed to stir at room temperature for 3hrs. The reaction was monitored via TLC and stopped upon consumption of starting material. The solution was concentrated and purified via silica gel chromatography to yield pure carboxylic acid.

20 General Procedure I involved the hydrogenolysis of benzyl protected phosphate esters, illustrated in the synthetic scheme shown in FIG. 2, as would be known by those skilled in the art.

Synthesis of oxazole R1 = Phenyl derivatives.

 Phosphoric acid mono-[4-(4-hexylcarbamoyl-2-phenyl-oxazol-5-ylmethyl)-phenyl] ester (PGB2-107) (12aa, R1 = phenyl, R2 = hexyl); Reaction
25 of 11aa according to procedure I, yield after rpHPLC (78 %). ¹H NMR (MeOD)TM 0.83 (3H, t, J = 6.7 Hz, CH₃), 1.25-1.34 (8H, m, CH₂), 1.50-1.60 (2H, m, CH₂), 3.30 (2H, t, J = 7.3 Hz, CH₂), 4.37 (2H, s, CH₂), 7.06 (2H, d, J = 8.4 Hz, Ar-H), 7.23 (2H, d, J = 8.4 Hz, Ar-H), 7.39 (4H, dd, J = 5.1 and 1.8
30 Hz, Ar-H), 7.90 (1H, m, Ar-H); ¹³C NMR (MeOD)TM 14.7, 24.0, 28.1, 31.1, 32.2, 33.1, 40.5, 116.2, 122.1, 127.8, 129.1, 130.4, 130.6, 130.9, 137.0,

137.9, 151.2, 154.7, 168.2; HRMS (TOF MS-ES), calcd. for C₂₃H₂₈N₂O₆P [M+H] m/z = 459.1667, fnd. 459.1658; rpHPLC tR: condition (I) 17.106 (II) 15.995 minutes, purity 95 %.

Phosphoric acid mono-{4-[4-(3-methoxy-phenylcarbamoyl)-2-phenyl-oxazol-5-ylmethyl]-phenyl} ester (PGB2-099) (12ab, R1 = phenyl, R2 = 3-methoxy-aniline); Reaction of 11ab according to procedure I, yield after rpHPLC (89 %). ¹H NMR (MeOD)TM 3.80 (3H, s, CH₃), 6.68-6.72 (1H, m, Ar-H), 7.14 (2H, d, J = 8.3 Hz, Ar-H), 7.24 (2H, d, J = 5.1 Hz, Ar-H), 7.35 (2H, d, J = 8.3 Hz, Ar-H), 7.42-7.50 (4H, m, Ar-H), 8.02 (2H, dd, J = 7.4 and 3.4 Hz, Ar-H); ¹³C NMR (MeOD)TM 29.2, 59.2, 101.0, 111.5, 113.4, 119.4, 119.5, 122.2, 125.3, 125.32, 128.1, 128.2, 128.23, 130.1, 130.2, 135.4, 135.42, 138.4, 139.1, 139.5, 140.1, 152.1, 156.7, 163.1, 164.0; HRMS (TOF MS-ES), calcd. for C₂₄H₂₂N₂O₇P [M+H] m/z = 481.1158, fnd. 481.1165; rpHPLC tR: condition (I) 12.287 minutes, purity 99 %.

Phosphoric acid mono-{4-[4-(4-cyclohexyl-phenylcarbamoyl)-2-phenyl-oxazol-5-ylmethyl]-phenyl} ester (PGB2-105) (12ac, R1 = phenyl, R2 = 4-cyclohexyl-aniline); Reaction of 11ac according to procedure I, yield after rpHPLC (84 %). ¹H NMR (MeOD)TM 1.85-2.50 (10H, m, CH₂), 3.17 (1H, m, CH), 5.13 (2H, s, CH₂), 7.78 (2H, d, J = 8.4 Hz, Ar-H), 7.85 (2H, d, J = 8.4 Hz, Ar-H), 8.14 (3H, m, Ar-H), 8.25 (2H, d, J = 8.5 Hz, Ar-H), 8.65 (2H, dd, J = 5.8 and 1.9 Hz, Ar-H); ¹³C NMR (MeOD)TM 27.2, 28.0, 32.0, 35.7, 45.5, 121.7, 121.78, 122.0, 127.5, 127.8, 128.2, 130.1, 131.0, 131.0, 131.7, 132.2, 134.5, 136.7, 145.9, 156.8, 160.8, 161.7; HRMS (TOF MS-ES), calcd. for C₂₉H₃₀N₂O₆P [M+H] m/z = 533.1849, fnd. 533.1842; rpHPLC tR: condition (I) 16.137 (III) 16.480 minutes, purity 99 %.

Phosphoric acid mono-{4-[4-(4-bromo-phenylcarbamoyl)-2-phenyl-oxazol-5-ylmethyl]-phenyl} ester (PGB2-097) (12ad, R1 = phenyl, R2 = 4-bromo-aniline); Reaction of 11ad according to procedure I, yield after rpHPLC (79 %). ¹H NMR (MeOD)TM 4.52 (2H, s, CH₂), 7.14-7.20 (3H, m, Ar-H), 7.18 (2H, d, J = 8.5 Hz, Ar-H), 7.38 (4H, dd, J = 13.5 and 6.0 Hz, Ar-H), 7.48-7.52 (2H, m, Ar-H), 7.88 (2H, d, J = 7.8 Hz, Ar-H), 8.04 (2H, d, J = 7.8 and 4.0 Hz,

Ar-H); ¹³C NMR (MeOD)TM 32.0, 121.7, 121.9, 125.7, 127.6, 127.8, 129.9, 130.1, 131.0, 131.7, 132.2, 134.4, 139.1, 152.1, 157.0, 160.8, 161.8; HRMS; rpHPLC tR: condition (I) 10.970 (II) 8.266 minutes, purity 99 %.

Phosphoric acid mono-{4-[4-(3-bromo-phenylcarbamoyl)-2-phenyl-oxazol-5-ylmethyl]-phenyl} ester (PGB2-139) (12ae, R1 = phenyl, R2 = 3-bromo-aniline); Reaction of 11ae according to procedure I, yield after rpHPLC (83 %). ¹H NMR (MeOD)TM 4.50 (2H, s, CH₂), 7.15 (1H, d, J = 7.4 Hz, Ar-H), 7.18 (2H, d, J = 8.5 Hz, Ar-H), 7.34 (2H, d, J = 8.5 Hz, Ar-H), 7.38 (1H, t, J = 8.5 Hz, Ar-H), 7.51 (3H, m, Ar-H), 7.74 (2H, d, J = 8.6 Hz, Ar-H), 8.05 (2H, dd, J = 5.4 and 1.8 Hz, Ar-H); ¹³C NMR (MeOD)TM 32.4, 115.9, 118.7, 122.2, 122.24, 122.3, 125.0, 126.0, 127.9, 130.3, 130.4, 131.0, 132.5, 136.9, 137.5, 137.9, 149.8, 157.7, 150.9, 165.7; rpHPLC tR: condition (I) 15.682 (II) 14.019 minutes, purity 98 %.

Synthesis of oxazole R1 = Naphthyl derivatives.

Phosphoric acid mono-[4-(4-hexylcarbamoyl-2-naphthalen-1-yl-oxazol-5-ylmethyl)-phenyl] ester (PGB2-227) (12ca, where R1 = naphthyl, R2 = hexyl); Reaction of 11ca according to procedure I, yield after rpHPLC (74 %). ¹H NMR (MeOD)TM 0.89 (3H, t, J = 6.9 Hz, CH₃), 1.23-1.44 (6H, m, CH₂), 1.59-1.68 (2H, m, CH₂), 3.39 (2H, t, J = 7.3 Hz, CH₂), 4.50 (2H, s, CH₂), 7.13 (2H, d, J = 8.5 Hz, Ar-H), 7.37 (2H, d, J = 8.5 Hz, Ar-H), 7.50-7.64 (3H, m, Ar-H), 7.90 (1H, d, J = 8.1 Hz, Ar-H), 7.99 (1H, d, J = 8.1 Hz, Ar-H), 8.09 (1H, d, J = 7.3 Hz, Ar-H), 9.13 (1H, d, J = 8.6 Hz, NH); ¹³C NMR (MeOD)TM 14.7, 24.1, 28.2, 31.1, 32.3, 33.1, 41.6, 116.3(2xC), 122.1, 125.2, 125.9, 126.5, 127.9 (2xC), 129.1, 129.6, 130.1, 131.3 (3xC), 133.9, 134.9, 135.8, 151.4, 156.2, 160.3; HRMS (TOF MS-ES+), calcd. for C₂₇H₃₀NO₆P [M+H]⁺ m/z = 509.1856, fnd. 509.1842; rpHPLC tR: condition (I) 13.489 (II) 12.213 minutes, purity 100 %.

Phosphoric acid mono-{4-[4-(3-methoxy-phenylcarbamoyl)-2-naphthalen-1-yl-oxazol-5-ylmethyl]-phenyl} ester (PGB4-091); Reaction of 11cb according to procedure I, yield after rpHPLC (45 %). ¹H NMR (MeOD)TM 3.85 (3H, s, CH₃), 4.61 (2H, s, CH₂), 6.76 (1H, td, J = 6.4 and 2.5 Hz, Ar-H),

7.21 (2H, d, J = 8.4 Hz, Ar-H), 7.29-7.32 (2H, m, Ar-H), 7.45 (2H, d, J = 8.4 Hz, Ar-H), 7.50-7.53 (1H, m, Ar-H), 7.59 (2H, dd, J = 8.1 and 7.3 Hz, Ar-H), 7.69 (1H, ddd, J = 8.5, 6.8 and 1.3 Hz, Ar-H), 7.97 (1H, d, J = 7.8 Hz, Ar-H), 8.06 (1H, d, J = 8.2 Hz, Ar-H), 8.17 (1H, dd, J = 7.3 and 1.0 Hz, Ar-H), 9.12 (1H, dd, J = 8.6 Hz, Ar-H); ¹³C NMR (MeOD)TM 32.4, 56.1, 108.1, 111.8, 114.6, 122.1, 124.5, 126.4, 127.2, 127.9, 129.2, 129.8, 130.1, 131.0, 131.4, 131.6, 132.0, 133.3, 134.7, 135.8, 140.6, 152.4, 157.3, 161.0, 162.0, 162.3; HRMS (TOF MS-ES+), calcd. for C₂₈H₂₄NO₇P [M+H]⁺ m/z = 531.1331, fnd. 531.1321; rpHPLC tR: condition (I) 13.064 (II) 11.925 minutes, purity 100 %.

10 Phosphoric acid mono-{4-[4-(4-cyclohexyl-phenylcarbamoyl)-2-naphthalen-1-yl-oxazol-5-ylmethyl]-phenyl} ester (PGB2-067); Reaction of 11cc according to procedure I, yield after rpHPLC (79 %). ¹H NMR (DMSO) 1.20-1.41 (5H, m, CH₂), 1.65-1.82 (5H, m, CH₂), 2.49, (1H, tt, J = 10.1 and 2.6 Hz, Ar-H), 4.51 (2H, s, CH₂), 7.11 (2H, d, J = 7.9 Hz, Ar-H), 7.21 (2H, d, J = 8.3 Hz, Ar-H), 7.31 (2H, d, J = 7.9 Hz, Ar-H), 7.64 (2H, dd, J = 14.3 and 7.1 Hz, Ar-H), 7.70 (1H, dd, J = 8.1 and 7.2 Hz, Ar-H), 7.74 (2H, d, J = 8.4 Hz, Ar-H), 8.03 (1H, d, J = 8.4 Hz, Ar-H), 8.13 (1H, d, J = 8.1 Hz, Ar-H), 8.18 (1H, d, J = 7.2 Hz, Ar-H), 9.24 (1H, d, J = 8.4 Hz, Ar-H), 10.04 (1H, s, NH); ¹³C NMR (DMSO)TM 25.6, 26.4, 30.5, 34.0, 43.3, 120.3, 121.1, 122.3, 125.2, 126.0, 126.6, 126.63, 127.9, 128.2, 129.2, 129.4, 130.5, 131.8, 133.5, 135.9, 143.4, 155.1, 158.1, 159.6; HRMS (TOF MS-ES+), calcd. for C₂₇H₃₀NO₆P [M+H]⁺ m/z = 509.1856, fnd. 509.1842; rpHPLC tR: condition (I) 15.019 (II) 14.914 minutes, purity 93 %.

Synthesis of Thiazole R1 = Phenyl derivatives

25 Phosphoric acid mono-[4-(4-hexylcarbamoyl-2-phenyl-thiazol-5-ylmethyl)-phenyl] ester (PGB3-139) (23aa, R1 = phenyl, R2 = hexyl); Reaction of 22aa according to procedure F, yield after rpHPLC (85 %). ¹H NMR (MeOD)TM 0.86 (3H, t, J = 6.7 Hz, CH₃), 1.25-1.39 (6H, m, CH₂), 1.59 (2H, m, CH₂), 3.34 (2H, t, J = 7.2 Hz, CH₂), 4.62 (2H, s, CH₂), 7.10 (2H, d, J = 8.2 Hz, Ar-H), 7.27 (2H, d, J = 8.0 Hz, Ar-H), 7.36-7.39 (3H, m, Ar-H), 7.87 (2H, dd, J = 6.0 and 2.4 Hz, Ar-H); ¹³C NMR (MeOD)TM 14.4, 23.7, 27.8, 30.7,

30

32.7, 32.9, 40.3, 121.7, 127.4, 130.1, 130.9, 131.6, 134.2, 137.7, 144.5, 146.8, 152.3, 164.5, 165.9; HRMS (TOF MS-ES), calcd. for C₂₄H₂₂N₂O₆PS [M+H] m/z = 497.0936, fnd. 497.0958; rpHPLC tR: condition (I) 12.518 (II) 11.103 minutes, purity 100 %.

- 5 Phosphoric acid mono-{4-[4-(3-methoxy-phenylcarbamoyl)-2-phenyl-thiazol-5-ylmethyl]-phenyl} ester (PGB3-143) (23ab, R1 = phenyl, R2 = 3-methoxy aniline); Reaction of 22ab according to procedure F, yield after rpHPLC (82 %). ¹H NMR (MeOD)TM 3.80 (2H, s, CH₃), 4.69 (2H, s, CH₂), 6.71 (1H, dt, J = 6.5 and 2.5 Hz, Ar-H), 7.16 (2H, d, J = 8.5 Hz, Ar-H), 7.23-7.27 (2H, m, Ar-H), 7.32 (2H, d, J = 8.2 Hz, Ar-H), 7.43-7.48 (4H, m, Ar-H), 7.95-7.98 (2H, m, Ar-H); HRMS (TOF MS-ES⁺), calcd. for C₂₄H₂₂N₂O₆SP [M+H] m/z = 497.0936, fnd. 497.0958; rpHPLC tR: condition (I) 12.667 minutes, purity 99 %.

- 15 Phosphoric acid mono-{4-[4-(4-cyclohexyl-phenylcarbamoyl)-2-phenyl-thiazol-5-ylmethyl]-phenyl} ester (PGB3-147) (23ac, R1 = phenyl, R2 = 4-cyclohexyl phenyl); Reaction of 22ac according to procedure F, yield after FCC (67 %, 33 % ethyl acetate in hexanes). ¹H NMR (DMSO)TM 1.19-1.42 (6H, m, CH₂), 1.69 (1H, d, J = 13.5 Hz, CH₂), 1.78 (2H, d, J = 8.3 Hz, CH₂), 2.52 (1H, m, CH), 4.65 (2H, s, CH₂), 7.11 (2H, s(broad), Ar-H), 7.21 (2H, d, J = 7.4 Hz, Ar-H), 7.29 (2H, s(broad), Ar-H), 7.49 (2H, s(broad), Ar-H), 7.74 (2H, d, J = 7.4 Hz, Ar-H), 7.95 (1H, t, J = 6.1 Hz, Ar-H), 8.05 (2H, m, Ar-H), 10.15 (1H, s, NH); HRMS (TOF MS-ES⁺), calcd. for C₂₆H₂₄NO₄ [M+H] m/z = 475.1465, fnd. 475.1457; rpHPLC tR: condition (I) 16.033, purity 100 %.

Synthesis of Thiazole R1 = Naphthyl derivatives

- 25 Phosphoric acid mono-[4-(4-hexylcarbamoyl)-2-naphthalen-1-yl-thiazol-5-ylmethyl]-phenyl} ester (PGB3-291) (23bb, R1 = naphthyl, R2 = 4-methoxy phenyl) (PGB3-291) (23ba, R1 = naphthyl, R2 = hexyl aniline); ¹H NMR (CDCl₃) 0.83 (3H, t, J = 6.5 Hz, CH₃), 1.24-1.38 (6H, m, CH₂), 1.50-1.51 (2H, m, CH₂), 3.36-3.39 (2H, m, CH₂), 4.57 (2H, s, CH₂), 7.04-7.20 (3H, m, Ar-H), 7.38-7.60 (4H, m, Ar-H), 7.75 (1H, s, Ar-H), 7.84 (2H, t, J = 8.3 Hz, Ar-H), 8.55 (1H, d, J = 7.6 Hz, Ar-H); ¹³C NMR (CDCl₃) 13.9, 22.5, 26.5, 29.3,

31.4, 32.0, 39.7, 120.9, 125.0, 125.3, 126.4, 127.3, 128.4, 128.7, 129.7, 130.2, 130.7, 133.9, 146.5, 149.5, 155.01, 163.7; HRMS (TOF MS-ES+), calcd. for C₂₇H₃₀N₂O₅PS [M+H] m/z = 525.1596, fnd. 525.1579; rpHPLC tR: condition (I) 15.908, (II) 16.140 minutes, purity 99 %.

5 Phosphoric acid mono-{4-[4-(3-methoxy-phenylcarbamoyl)-2-naphthalen-1-yl-thiazol-5-ylmethyl]-phenyl} ester (PGB4-003) (23bb, R1 = naphthyl, R2 = 4-methoxy phenyl); ¹H NMR (CDCl₃) . 3.67 (3H, s, CH₃), 4.50 (2H, s, CH₂), 6.57 (1H, d, J = 8.0 Hz, Ar-H), 6.96-7.46 (11H, m, Ar-H), 7.68-7.78 (2H, m, Ar-H), 8.50 (1H, d, J = 6.7 Hz, Ar-H), 9.34 (1H, s, NH); ¹³C NMR (CDCl₃)
10 . 33.1, 56.0, 106.1, 110.9, 112.8, 125.6, 125.8, 127.1, 128.1, 129.1, 129.3, 130.3, 130.35, 130.5, 130.6, 131.5, 134.6, 137.9, 139.5, 150.4, 153.9, 161.8, 165.0; HRMS (TOF MS-ES+), calcd. for C₂₈H₂₄N₂O₆PS [M+H] m/z = 547.1091, fnd. 547.1093; rpHPLC tR: condition (I) 14.935, (II) 15.048 minutes, purity 97 %.

15 Phosphoric acid mono-{4-[4-(4-cyclohexyl-phenylcarbamoyl)-2-naphthalen-1-yl-thiazol-5-ylmethyl]-phenyl} ester (PGB4-289) (23bc, R1 = naphthyl, R2 = 4-cyclohexyl aniline); ¹H NMR (CDCl₃) 1.22- 1.39 (5H, m, CH₂), 1.67 (1H, d, J = 12.0 Hz, CH), 1.70-1.81 (4H, m, CH₂), 2.41 (1H, t, J = 11.6 Hz, CH), 4.59 (2H, s, CH₂), 6.95-7.17 (6H, m, Ar-H), 7.38 (1H, t, J = 7.5
20 Hz, Ar-H), 7.42-7.49 (4H, m, Ar-H), 7.54 (1H, d, J = 7.0 Hz, Ar-H), 7.81 (2H, t, J = 6.4 Hz, Ar-H), 8.56 (1H, d, J = 8.2 Hz, Ar-H); ¹³C NMR (CDCl₃) 26.5, 27.2, 32.7, 34.8, 44.4, 120.9, 121.3, 125.4, 125.7, 126.8, 127.7, 127.8, 128.8, 129.2, 130.3, 130.5, 131.2, 134.3, 135.2, 136.5, 142.8, 145.0, 148.0, 149.8, 161.0, 164.1; HRMS (TOF MS-ES+), calcd. for C₂₇H₃₀N₂O₅PS [M+H] m/z =
25 525.1596, fnd. 525.1613; rpHPLC tR: condition (I) 13.898, (II) 13.025 minutes, purity 99 %.


 Trifluoro-methanesulfonic acid 4-[4-(4-cyclohexyl-phenylcarbamoyl)-2-phenyl-oxazol-5-ylmethyl]-phenyl ester (PGB3-203) (XX, R1 = phenyl, R2 = 4-cyclohexyl aniline); ¹H NMR (CDCl₃)TM 1.23-1.45 (4H, m, CH₂), 1.68-2.93
30 (6H, m, CH₂), 2.50 (1H, t, J = 11.5 and 3.0 Hz, CH), 4.58 (2H, s, CH₂), 7.21 (2H, d, J = 8.4 Hz, Ar-H), 7.23 (2H, d, J = 8.4 Hz, Ar-H), 7.46-7.53 (4H, m, Ar-

12

H), 7.61 (2H, d, J = 8.4 Hz, Ar-H), 8.02 (2H, dd, J = 6.55 and 3.1 Hz, Ar-H), 8.86 (1H, s, NH); ¹³C NMR (CDCl₃)TM 26.0, 26.8, 31.32, 34.5, 43.9, 120.0, 121.5, 126.4, 126.5, 127.3, 128.9, 130.7, 131.2, 135.1, 137.3, 144.6, 148.7, 153.9, 159.5; LRMS (MS-ES+), m/z = 585.1 [M+H]; rpHPLC tR: condition (I) 16.360, (II) 16.375 minutes, purity 99 %.

2-{4-[4-(4-Cyclohexyl-phenylcarbamoyl)-2-phenyl-oxazol-5-ylmethyl]-phenoxy}-malonic acid (PGB3-213) (XX, R₁ = phenyl, R₂ = 4-cyclohexyl aniline); ¹H NMR (CDCl₃)TM 1.20-1.48 (5H, m, CH₂), 1.68-1.86 (5H, m, CH₂), 2.46 (1H, t, J = 8.4 Hz, CH), 4.43 (2H, s, CH₂), 5.15 (1H, s, CH), 6.91 (2H, d, J = 7.3 Hz, Ar-H), 7.18 (2H, d, J = 8.4 Hz, Ar-H), 7.29 (2H, d, J = 7.3 Hz, Ar-H), 7.44-7.47 (3H, m, Ar-H), 7.57 (2H, d, J = 8.4 Hz, Ar-H), 7.99 (2H, t, J = 3.7 Hz, Ar-H), 9.60 (1H, s, NH); ¹³C NMR (CDCl₃) 227.3, 28.0, 31.9, 35.8, 45.5, 96.3, 116.6, 122.0, 127.5, 127.8, 128.2, 130.1, 131.0, 131.5, 131.7, 132.1, 136.7, 145.9, 157.1, 160.7, 161.8; rpHPLC tR: condition (I) 14.347, (II) 13.821 minutes, purity 95 %.

Accordingly, a first embodiment of the invention is a compound having a generic chemical structure according to the following formula:




20

wherein X comprises oxygen or sulfur, R¹ comprises a phenyl or naphthyl group, R² comprises an amide group and R³ comprises a phosphate group. This embodiment of the invention is a generic molecule which forms the basic structure from which the various other embodiments are derived. This and other embodiments of the invention are shown in Table I. These compounds may be prepared according to the scheme shown in FIG. 2. QQ


Another compound of the invention is one having a chemical structure according to the formula:

13




wherein X is oxygen, R¹ is a phenyl group, R² is a naphthyl amide group and R³ is a phosphate group.

Yet another compound of the invention has a chemical structure
5 according to the formula:



wherein X is sulfur, R¹ is a phenyl group,


R² is



and R³ is a phosphate group.


10

Another derivative of the present invention includes a compound
having a chemical structure according to the formula:



wherein X is oxygen, R¹ is a phenyl group,

R² is




and R³ is a phosphate group.

15

Yet an additional compound included in the invention is one having a
chemical structure according to the formula:


14




wherein X is sulfur, R¹ is a naphthyl group,

R² is  and R³ is a phosphate group.

- 5 Another embodiment of the invention includes a compound having a chemical structure according to the formula:




wherein X is oxygen, R¹ is a naphthyl group,


R² is  and R³ is a phosphate group.

10

A further embodiment of the invention is a compound having a chemical structure according to the formula:



wherein X is sulfur, R¹ is a naphthyl group,

R² is  and R³ is a phosphate group.

15

BRIEF DESCRIPTION OF THE DRAWINGS

Some of the features, advantages, and benefits of the present invention having been stated, others will become apparent as the description proceeds when taken in conjunction with the accompanying drawings, presented for solely for exemplary purposes and not with intent to limit the invention thereto, and in which:

FIG. 1A, according to an embodiment of the present invention, shows the active site conformation of ISS610, as determined by flexible ligand docking in the active site of STAT3 (PDB ID: 1BG1) using GOLD 3.0; lead peptidomimetic ISS610 displays limited occupation of the active site; expansion site indicated by arrow; FIG. 1B shows how oxazole 10 replicates the functionality projection of ISS610 and accesses the previously unoccupied region of the SH2 domain (red = hydrophobic, blue = hydrophilic);

FIG. 2 depicts a reaction scheme including the following conditions: a) R'COOH, HBTU, DIPEA, DMF; b) PPh₃, I₂, TEA, CH₂Cl₂; c) 2N NaOH, THF; d) *t*Bu-trichloro acetamide, BF₃(OEt)₂, CH₂Cl₂; e) H₂, Pd/C, THF; f) dibenzylidiisopropyl phosphoroamidate, tetrazole, *m*CPBA, CH₂Cl₂; g) TFA, Et₅SiH, CH₂Cl₂; h) R²COOH, HBTU, DIPEA, DMF; i) H₂, Pd/C, EtOAc, HBTU = 2-(1H-benzotriazol-1-yl)-1,1,3,3-tetra methyluronium hexafluorophosphate (DIPEA = diisopropylethylamine, DMF = *N,N* dimethylformamide, TEA = triethylamine, TFA = trifluoroacetic acid).

FIG. 3A shows EMSA data for *in vitro* disruption of STAT3 dimers by compound 10, as shown in Table 1; FIG. 3B presents *in vivo* disruption of NIH3T3/vSrc with compound 10 (100 μM) over 6, 24 and 48 hour periods;

FIG. 4 shows a line graph illustrating the dose dependent effects of compound 10 upon NIH3T3, a mouse breast tissue cell line, and NIH3T3/vSrc cell lines using WST-1 mediated spectrophotometric analysis;

FIG. 5 depicts an EC₅₀ determination for compound 19 induced effects upon pancreatic human cancer cell lines (panc-1) evaluated using WST-1;

and

FIG. 6 is a line graph illustrating results of a competitive binding experiment between the fluorescent probe 5-carboxyfluorescein-GpYLPQTV-NH₂ and oxazoles 10, 15, 17 as well as unlabeled Ac-pYLPQTV-NH₂ peptide to STAT3 protein; whereas Ac-pYLPQTV-NH₂ displays a 200 nM affinity towards STAT3, and oxazole compounds 10, 15, and 17 do not interact significantly with STAT3.

DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENT

The present invention will now be described more fully hereinafter with reference to the accompanying drawings, in which preferred embodiments of the invention are shown. Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention pertains. Although methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention, suitable methods and materials are described below. Any publications, patent applications, patents, or other references mentioned herein are incorporated by reference in their entirety. In case of conflict, the present specification, including any definitions, will control. In addition, the materials, methods and examples given are illustrative in nature only and not intended to be limiting. Accordingly, this invention may be embodied in many different forms and should not be construed as limited to the illustrated embodiments set forth herein. Rather, these illustrated embodiments are provided so that this disclosure will be thorough and complete, and will fully convey the scope of the invention to those skilled in the art. Other features and advantages of the invention will be apparent from the following detailed description, and from the claims.

Aspects of the presently disclosed invention were published by P. T. Gunning et al., Targeting Protein-Protein Interactions: Suppression of STAT3 Dimerization with Rationally Designed Small-Molecule, Nonpeptidic SH2

Domain Binders, *ChemBioChem* 2008, 9, 2800-2803. As noted above, this publication is incorporated herein by reference in its entirety.

The crystal structure of the STAT3-SH2 domain reveals a shallow triangular pocket comprising two hydrophobic sites and a hydrophilic phosphate recognition pocket. Initial peptidomimetic studies failed to identify agents which simultaneously projected functionality within all three pockets; see FIG. 1A.

The present investigation was directed to ascertaining whether a tri-substituted heterocyclic scaffold could effectively access these three pockets; see FIG. 1B. Flexible ligand-docking studies (GOLD) directed the design and assembly of oxazole and thiazole scaffolds. A series of oxazole inhibitors was prepared as outlined in FIG. 2. GOLD docking studies predicted a focused set of diversity elements deemed suitable for occupation of the SH2 domain. Both R¹ and R² appendages were predominantly hydrophobic in nature to interact with the hydrophobic surface presented by residues present in the upper (Phe716, Met660, Pro715) and lower right (Ser636, Arg595, Lys591) pockets of the STAT3 active site (FIGS. 1A and B).

A screening process evaluated *in vitro* disruption of STAT3(dimer)-DNA formation through a previously published EMSA based assays, giving a valuable insight into the inhibitor's mode of action against the STAT3 homodimer. An initial series of STAT3 oxazole and thiazole inhibitors is shown in Table 1. Oxazole 7 was prepared as a control agent, closely resembling lead peptidomimetic ISS610, to explore the efficacy of compounds not projecting sizable appendages from the R² position. STAT3 DNA binding disruption by compound 7 was shown to be negligible, presumably due to poor inhibitor-protein complementarity. Substitution of ISS610 at the acidic terminus had been shown previously to decrease potency in all cases studied, suggesting that the oxazole scaffold is able to project substituents in a substantially different orientation than could be achieved with a peptide based inhibitor (FIG. 1).

Five compounds shown in Table 1 displayed IC_{50} values below 100 μ M, with oxazole 10 showing significant dimer disruption potential (IC_{50} = 33 μ M). Data suggest limited isoform specificity for STAT3 over STAT1 protein.

Dramatic effects were observed though replacement of the central core in several cases. Examples of such effects include compounds 10 and 11 as shown in Table 1, where the high potency displayed by the oxazole analog 10 (IC_{50} = 33 μ M (see FIG. 2A.) is severely diminished in the analogous thiazole 11 (IC_{50} = 775 μ M). Conversely, thiazole 16 (IC_{50} = 25 μ M) exhibits improvements in activity compared with the corresponding oxazole 15 (IC_{50} = 58 μ M). Molecular modeling studies showed that the thiazole scaffolds afforded a functional group orientation with higher protein surface complementarity.


Docking studies predict a H-bond between Lys591 and the heterocyclic core oxygen or sulfur, which is expected to be more favorable with harder oxazole oxygen atoms than softer thiazole sulfur. In almost all examples, increased potency is derived from a thiazole core.

Control oxazole compound 12, containing the most potent arrangement of R^1 and R^2 elements, but lacking a phosphate group, was shown to be essentially devoid of activity. Further non -phosphorylated scaffolds were prepared and found to be impotent STAT3 disruptors.

Given the extended planar aryl-oxazole construct and the propensity of such scaffolds to intercalate with DNA, experiments were conducted to discount potential DNA interaction. It was found using fluorescence spectroscopy that DNA -bound ethidium bromide did not vary upon addition of compound 10, which can thus be considered inert towards DNA.

Work was undertaken to establish the affinity of the lead oxazole 10 for the inactive (unphosphorylated) STAT3 monomer to help determine the mode of action. By using fluorescence spectroscopy, K_i values were calculated through displacement of an SH2 binding fluorescein-labeled GpYLPQTV-NH2 peptide. The most potent inhibitors were found to have low affinity with the

Table 1. IC₅₀ values (μM) for the inhibition of STAT3 DNA-binding activity *in vitro* via oxazole and thiazole analogs of ISS610.



where X = O or S

Compound Number	R ¹	R ²	Scaffold Core	R ³	IC ₅₀ Values (μM) ^[a]
7				PO ₃ H ₂	>1000
8				PO ₃ H ₂	>1000
9				PO ₃ H ₂	150
10				PO ₃ H ₂	33
11				PO ₃ H ₂	775
12				H	>1000
13				PO ₃ H ₂	90
14				PO ₃ H ₂	28
15				PO ₃ H ₂	58
16				PO ₃ H ₂	25
17				PO ₃ H ₂	255
18				PO ₃ H ₂	350
19				PO ₃ H ₂	125

[a] Inhibitor concentration required to decrease STAT3-DNA binding twofold.

unphosphorylated STAT3 monomer (10 and 15, $K_i \sim 1$ mM; FIG. 6). These results were attributed to the smaller size of the oxazole scaffolds relative to the phosphopeptide, which is predicted to make contacts with both the BG and EF loops that recognize ligand residues at the pTyr+3 site. Structural limitations of the inhibitors might preclude effective interactions with the SH2 domain and reduce their ability to displace the extended peptide sequence.

Despite the inherent difficulties associated with the cell permeability of phosphate derivatives, promising whole-cell activities were observed for several lead compounds. Initial *in vitro* whole-cell experiments were conducted against normal mouse NIH-3T3 fibroblasts and v-src-transformed counterparts (NIH-3T3/v-src) that harbor aberrant STAT3. Inhibitor effects upon cell viability, proliferation, and cytotoxicity were assessed through WST-1, a cell proliferation reagent that measures the metabolic activity of viable cells. The most potent *in vitro* inhibitor, compound 10, displayed at least ten-fold selectivity toward malignant NIH-3T3/v-src fibroblasts with aberrant STAT3 ($EC_{50} = 120$ μ M) and negligible effects toward normal NIH-3T3 fibroblasts, in which STAT3 pathways are tightly regulated. Conversely, the suppression by lead peptidomimetic ISS610 in whole cells required millimolar concentrations of inhibitor. It is assumed that the predominantly hydrophobic nature of these compounds facilitated successful permeation of the cell membrane despite the phosphate.

In addition, cell-based EC_{50} values were determined for potent inhibitors against human breast (MDA-MB-231) cancer cell lines (Table 2). Oxazole 10 had the best activity against breast cancer ($EC_{50} = 180$ μ M) and NIH-3T3/v-src cells ($EC_{50} = 120$ μ M) and lacked toxicity for control NIH-3T3 cells.

In summary, herein are disclosed the first rationally designed small-molecule inhibitors of STAT3 dimerization that disrupt STAT3-mediated cell proliferation pathways. Suitably substituted oxazole and thiazole scaffolds, derived from peptidomimetic leads, disrupted STAT3:STAT3–DNA-binding activity *in vitro* at low micromolar concentrations, but showed low affinity to the

unphosphorylated STAT3 monomer. This might suggest that the present compounds preferentially bind with activated STAT3, a hypothesis which is further supported by the lack of activity against control cells (NIH-3T3); however, this remains to be verified. Lead agents showed potency and specific human cancer cell lines and negligible toxicity towards normal NIH-3T3 fibroblasts. The present studies highlight the widely acknowledged belief that STAT3 is a potent target for disruption by small-molecule inhibitors for novel anticancer drug development and that targeting of STAT3 will require yet a further level of investigation.

Table 2. EC₅₀ values for selected inhibitors against constitutively activated STAT3 containing cell lines NIH3T3/vSrc, Panc-1, MDA-231 and non-activated STAT3 NIH3T3 cells.


Compound No.	Panc-1 EC ₅₀ (μM)	MDA-231 EC ₅₀ (μM)	NIH3T3 EC ₅₀ (μM)	NIH3T3/vSrc
10	>1000	180	>1000	120
14	>1000	>1000	>1000	480
16	>1000	300	>1000	145
19	10	>1000	>1000	700

Accordingly, in the drawings and specification there have been disclosed typical preferred embodiments of the invention and although specific terms may have been employed, the terms are used in a descriptive sense only and not for purposes of limitation. The invention has been described in considerable detail with specific reference to these illustrated embodiments. It will be apparent, however, that various modifications and changes can be made within the spirit and scope of the invention as described in the foregoing specification and as defined in the appended claims.

22

THAT WHICH IS CLAIMED:

1. A compound having a chemical structure according to the formula:



5


wherein X comprises oxygen or sulfur, R¹ comprises a phenyl or naphthyl group, R² comprises an amide group and R³ comprises a phosphate group.

10

2. A pharmaceutically acceptable salt of the compound of claim 1.
3. A pharmaceutically acceptable composition containing the compound of claim 1 or a salt thereof.

15

4. A compound having a chemical structure according to the formula:




wherein X is oxygen, R¹ is a phenyl group, R² is a naphthyl amide group and R³ is a phosphate group.

20

5. A pharmaceutically acceptable salt of the compound of claim 4.
6. A pharmaceutically acceptable composition containing the compound of claim 4 or a salt thereof.

25

7. A method of treating a mammalian cell having a dysfunctional STAT3 protein, the method comprising contacting the cell with the compound of claim 4 or a pharmaceutically acceptable salt thereof.
8. The method of claim 7, wherein the dysfunctional STAT3 protein is a constitutive protein in the cell.
9. A method of treating a mammalian breast cancer cell, comprising contacting the cell with the compound of claim 4 or a pharmaceutically acceptable salt thereof.
10. The method of claim 9, wherein the mammalian breast cancer cell is a human breast cancer cell.
11. A compound having a chemical structure according to the formula:




wherein X is sulfur, R¹ is a phenyl group,


R² is  and R³ is a phosphate group.

12. A pharmaceutically acceptable salt of the compound of claim 11.
13. A pharmaceutically acceptable composition containing the compound of claim 11 or a salt thereof.

14. A method of treating a mammalian cell having a dysfunctional STAT3 protein, the method comprising contacting the cell with the compound of claim 11 or a pharmaceutically acceptable salt thereof.
15. The method of claim 14, wherein the dysfunctional STAT3 protein is a constitutive protein in the cell.
16. A method of treating a mammalian breast cancer cell, comprising contacting the cell with the compound of claim 11 or a pharmaceutically acceptable salt thereof.
17. The method of claim 16, wherein the mammalian breast cancer cell is a human breast cancer cell.
18. A compound having a chemical structure according to the formula:



wherein X is oxygen, R¹ is a phenyl group,

R² is  and R³ is a phosphate group.


19. A pharmaceutically acceptable salt of the compound of claim 18.
20. A pharmaceutically acceptable composition containing the compound of claim 18 or a salt thereof.
21. A method of treating a mammalian cell having a dysfunctional STAT3 protein, the method comprising contacting the cell with the compound of claim 18 or a pharmaceutically acceptable salt thereof.

22. The method of claim 21, wherein the dysfunctional STAT3 protein is a constitutive protein in the cell.

5 23. A method of treating a mammalian breast cancer cell, comprising contacting the cell with the compound of claim 18 or a pharmaceutically acceptable salt thereof.

24. The method of claim 23, wherein the mammalian breast cancer cell is a
10 human breast cancer cell.

25. A compound having a chemical structure according to the formula:



wherein X is sulfur, R¹ is a naphthyl group,

15 R² is  and R³ is a phosphate group.

26. A pharmaceutically acceptable salt of the compound of claim 25.

27. A pharmaceutically acceptable composition containing the compound
20 of claim 25 or a salt thereof.

28. A method of treating a mammalian cell having a dysfunctional STAT3 protein, the method comprising contacting the cell with the compound of claim 25 or a pharmaceutically acceptable salt thereof.

25


29. The method of claim 28, wherein the dysfunctional STAT3 protein is a constitutive protein in the cell.

30. A method of treating a mammalian breast cancer cell, comprising contacting the cell with the compound of claim 25 or a pharmaceutically acceptable salt thereof.

5

31. The method of claim 30, wherein the mammalian breast cancer cell is a human breast cancer cell.

32. A compound having a chemical structure according to the formula:



10

wherein X is oxygen, R¹ is a naphthyl group,

R² is and R³ is a phosphate group.

33. A pharmaceutically acceptable salt of the compound of claim 32.

15

34. A pharmaceutically acceptable composition containing the compound of claim 32 or a salt thereof.

35. A method of treating a mammalian cell having a dysfunctional STAT3 protein, the method comprising contacting the cell with the compound of claim 32 or a pharmaceutically acceptable salt thereof.

20


36. The method of claim 35, wherein the dysfunctional STAT3 protein is a constitutive protein in the cell.

25


37. A method of treating a mammalian breast cancer cell, comprising contacting the cell with the compound of claim 32 or a pharmaceutically acceptable salt thereof.

5 38. The method of claim 37, wherein the mammalian breast cancer cell is a human breast cancer cell.

39. A compound having a chemical structure according to the formula:



10 wherein X is sulfur, R¹ is a naphthyl group,

R² is  and R³ is a phosphate group.

40. A pharmaceutically acceptable salt of the compound of claim 39.

15 41. A pharmaceutically acceptable composition containing the compound of claim 39 or a salt thereof.

42. A method of treating a mammalian cell having a dysfunctional STAT3 protein, the method comprising contacting the cell with the compound of claim 20 39 or a pharmaceutically acceptable salt thereof.

43. The method of claim 42, wherein the dysfunctional STAT3 protein is a constitutive protein in the cell.

25 44. The method of claim 42, wherein the cell is a human pancreatic cancer cell.

45. A method of treating a mammalian breast cancer cell, comprising contacting the cell with the compound of claim 39 or a pharmaceutically acceptable salt thereof.

- 5 46. The method of claim 45, wherein the mammalian breast cancer cell is a human breast cancer cell.

1/4




FIG. 1

2/4




FIG. 2




FIG. 3

3/4




FIG. 4

4/4




FIG. 5




FIG. 6

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US 09/57291

A. CLASSIFICATION OF SUBJECT MATTER

IPC(8) - C07D 215/00 (2009.01)

USPC - 546/164

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

USPC - 546/164 (see search terms below)

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched
USPC - 546/268.4; 544/284; 544/353; 514/342; 514/314 (see search terms below)Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)
USPTO-WEST - PGPB,USPT,USOC,EPAB,JPAB keywords: STAT3 inhibitor, cancers, treatment, methods, oxazole-based, cell, human, peptidomimetic, contacting, breast, S3I-M2001, salt, composition, Stat3, homodimer, DNA complex, crystal structure, SH2 domain, docking, virtual screening. INTERNET search - Google - same

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 2008/070697 A2 (TURKSON et al.) 12 June 2008 (12.06.2008), Abstract; pg 3, ln 25-29; pg 4, ln 1-10.	1-3 and 32-38
Y		4-31 and 39-46
Y	FLETCHER et al., Molecular Approaches towards the Inhibition of the Signal Transducer and Activator of Transcription 3 (Stat3) Protein, ChemMedChem., 3(8), pg 1 - pg 22 [pp 1159-1168], 2008 August, pg 2; pg 7 - pg 10; Fig 2; Fig 10.	4-31 and 39-46

☐ Further documents are listed in the continuation of Box C.

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier application or patent but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search

11 November 2009 (11.11.2009)

Date of mailing of the international search report

20 NOV 2009

Name and mailing address of the ISA/US

Mail Stop PCT, Attn: ISA/US, Commissioner for Patents
P.O. Box 1450, Alexandria, Virginia 22313-1450

Facsimile No. 571-273-3201

Authorized officer:

Lee W. Young

PCT Helpdesk: 571-272-4300
PCT OSP: 571-272-7774